Remove 2024 Remove Nuclear Medicine Remove PET Scan Remove Radiology
article thumbnail

IMV: PET scan volumes continue to grow

AuntMinnie

In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% year over year, according to the newly published IMV 2024 PET Market Summary Report. In 2023, the average number of PET scans per fixed PET site (versus mobile PET) increased 6.7%

PET Scan 116
article thumbnail

Meet the Minnies 2024 semifinal candidates

AuntMinnie

The following is the list of candidates for the 2024 edition of the Minnies, AuntMinnie.com 's campaign to recognize the best and brightest in medical imaging. This year, hundreds of candidates have been selected as semifinalists for 14 categories, ranging from Most Influential Radiology Researcher to Best New Radiology Software.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. The nuclear radiologist, nuclear medicine technologist, and radiation safety team are all present to administer an infusion.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. The nuclear radiologist, nuclear medicine technologist, and radiation safety team are all present to administer an infusion.

article thumbnail

The rise of theranostics: Part 4 -- Women's theranostics on the horizon

AuntMinnie

Several presenters at the Society for Nuclear Medicine and Molecular Imaging's (SNMMI) 2024 meeting in Toronto shared new findings in women's studies. CAM-H2-I-131 is specific, reaches HER2 positive lesions, and is retained in lesions for at least seven days, according to research presented by Precirix during SNMMI 2024.

Disease 105